

IN THE CLAIMS

1. (previously presented) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size of less than 250 microns in diameter.

2. (previously presented) The dry powder inhalation composition according to claim 1, wherein the composition comprises less than 10% by weight of the composition of the active ingredient.

3. (previously presented) The dry powder inhalation composition according to claim 1 or claim 2, wherein the composition comprises from about 0.26 to about 1% by weight of the composition of the active ingredient.

4. (previously presented) The dry powder inhalation composition according to claim 1, which comprises from about 0.265 to about 0.5% by weight of the composition of the active ingredient.

5. (previously presented) The dry powder inhalation composition according to claim 1 or 4, wherein the carrier is lactose.

6. (currently amended) The dry powder inhalation composition according to claim 1 or 4, wherein the active ingredient is formoterol or a pharmaceutically acceptable derivative thereof.

7. (Canceled).

8. (previously presented) A capsule containing from 1 to 25 mg of a dry powder inhalation composition according to claim 1 or 4.

9. (previously presented) A multidose dry powder inhaler comprising a reservoir containing the dry powder inhalation composition of claim 1 or 4.

10. (previously presented) A method for the treatment of chronic obstructive pulmonary disease by the step of administering the dry powder inhalation composition of claim 1 or 4.

11. (currently amended) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 89 to about 110 microns in diameter.

12. (previously presented) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 50 to about 60 microns in diameter.

13. (previously presented) A dry powder inhalation composition consisting of (a) at least 0.25% by weight of the composition of an active ingredient with a mean particle size of less than 10 microns in diameter, and (b) a pharmaceutically acceptable particulate carrier with a mean particle size from about 60 to about 90 microns in diameter.

14. (currently amended) The dry powder inhalation composition according to claim 9, wherein said active ingredient is formoterol and said multidose dry powder inhaler is capable of producing a 6 mcg dose having a fine particle fraction of about 48%.

15. (currently amended) The dry powder inhalation composition according to claim 9; wherein said active ingredient comprises formoterol and said multidose dry powder inhaler is capable of producing a 12 mcg dose having a fine particle fraction of about 49%-54%.

16. (new) The dry powder inhalation composition according to claim 1 wherein the composition comprises at least 0.26% by weight of the composition of the active ingredient.